Alternative methods of cladribine administration
Alternative methods of cladribine administration
Nucleoside derivative cladribine treatment in hairy cell leukemia (HCL) is a rare example of treatment success in cancer. In fact, HCL is generally responsive to single-agent cladribine and only a minority of patients are refractory. Cladribine was originally administered intravenously as a continuous infusion at a dose of 0.1 mg/kg/day for 7 consecutive days. Subsequently cladribine has been administered intravenously, as a 2?h infusion for 5 consecutive days or weekly for 7 weeks, or subcutaneously. These regimens are all very effective but often show relevant toxicity. The subcutaneous route is easier to administer and may increase compliance of the patient. We have had the opportunity to investigate the efficacy and toxicity of subcutaneous cladribine given at the dose of 0.1 mg/kg/day for 5 or 7 days as a single course in newly diagnosed HCL requiring treatment, in an ongoing Italian multicenter clinical trial. Overall responses have been no different in the two arms, while a much lower infection rate was observed when cladribine was given at the lowest dose. Subcutaneous administration may be deemed a very convenient route since it does not require hospitalization. A reduced dosage of cladribine may also be advantageous since it may be associated with reduced toxicity and may set the dose needed for combinations with antibody treatments.
hairy cell leukemia, therapy, cladribine
34-37
Lauria, Francesco
f01f163b-abcb-4aad-b952-f4356692f519
Cencini, Emanuele
3dc5d188-96b0-4f7d-abb8-af4d22638d7e
Forconi, Francesco
ce9ed873-58cf-4876-bf3a-9ba1d163edc8
June 2011
Lauria, Francesco
f01f163b-abcb-4aad-b952-f4356692f519
Cencini, Emanuele
3dc5d188-96b0-4f7d-abb8-af4d22638d7e
Forconi, Francesco
ce9ed873-58cf-4876-bf3a-9ba1d163edc8
Abstract
Nucleoside derivative cladribine treatment in hairy cell leukemia (HCL) is a rare example of treatment success in cancer. In fact, HCL is generally responsive to single-agent cladribine and only a minority of patients are refractory. Cladribine was originally administered intravenously as a continuous infusion at a dose of 0.1 mg/kg/day for 7 consecutive days. Subsequently cladribine has been administered intravenously, as a 2?h infusion for 5 consecutive days or weekly for 7 weeks, or subcutaneously. These regimens are all very effective but often show relevant toxicity. The subcutaneous route is easier to administer and may increase compliance of the patient. We have had the opportunity to investigate the efficacy and toxicity of subcutaneous cladribine given at the dose of 0.1 mg/kg/day for 5 or 7 days as a single course in newly diagnosed HCL requiring treatment, in an ongoing Italian multicenter clinical trial. Overall responses have been no different in the two arms, while a much lower infection rate was observed when cladribine was given at the lowest dose. Subcutaneous administration may be deemed a very convenient route since it does not require hospitalization. A reduced dosage of cladribine may also be advantageous since it may be associated with reduced toxicity and may set the dose needed for combinations with antibody treatments.
This record has no associated files available for download.
More information
Published date: June 2011
Keywords:
hairy cell leukemia, therapy, cladribine
Organisations:
Cancer Sciences
Identifiers
Local EPrints ID: 358128
URI: http://eprints.soton.ac.uk/id/eprint/358128
ISSN: 1042-8194
PURE UUID: 996aeb5f-cde3-424b-8e68-c2c360292f0d
Catalogue record
Date deposited: 08 Oct 2013 10:09
Last modified: 15 Mar 2024 03:40
Export record
Altmetrics
Contributors
Author:
Francesco Lauria
Author:
Emanuele Cencini
Download statistics
Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.
View more statistics